Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AXETIL versus MANDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AXETIL versus MANDOL.
CEFUROXIME AXETIL vs MANDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime axetil is a prodrug that is hydrolyzed to cefuroxime, a second-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250–500 mg orally twice daily; for severe infections (e.g., pneumonia), 500 mg twice daily; for uncomplicated urinary tract infections, 250 mg twice daily; for Lyme disease, 500 mg twice daily for 20 days.
1-2 g IV or IM every 4-8 hours; maximum 12 g/day.
None Documented
None Documented
Clinical Note
moderateCefamandole + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefamandole."
Clinical Note
moderateCefamandole + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefamandole."
Clinical Note
moderateWarfarin + Cefamandole
"Warfarin may increase the anticoagulant activities of Cefamandole."
Clinical Note
moderatePhenprocoumon + Cefamandole
1.2-1.6 hours (normal renal function); prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min). For oral cefuroxime axetil, consider absorption and conversion to active cefuroxime.
Terminal elimination half-life is 1.2-1.8 hours in adults with normal renal function; prolonged to 4-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and >12 hours in severe impairment (CrCl <30 mL/min).
Renal: 70-90% unchanged by glomerular filtration and tubular secretion; biliary/fecal: <10%
Renal: 65-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~15-20% as active drug and metabolites; minor hepatic metabolism.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefamandole."